Nanda Kumar
Neurology · Manhattan, KSNPI 1861595001
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,574 of the $11,038 with a category attached, or 86.7%. It is spread thinly across 54 manufacturers, the largest accounting for just 15.4% — the pattern of someone who eats at a lot of different presentations.
Across 562 payments — averaging $19.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- UCB, Inc.$616
- Novartis$582
- Amgen$552
- Biogen$523
- EMD Serono, Inc.$480
- plus $7K from 48 others
What the payments were for
- Speaking & faculty fees$410%
- Travel & lodging$1,42213%
- Food & beverage$9,57487%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INFINITY$1,532
How this compares
$11,038 in reported general payments places this provider in the 80th percentile of 131 neurology providers in Kansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 21 | $90,859 |
| LamictalLamotrigine | 18 | $12,490 |
| NamzaricMemantine Hcl/Donepezil Hcl | 18 | $9,986 |
| RytaryCarbidopa/Levodopa | 15 | $7,685 |
| Lacosamide | 12 | $3,642 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 139 | $3,300 |
| Levetiracetam | 108 | $2,147 |
| Divalproex Sodium ErDivalproex Sodium | 17 | $1,371 |
| Ropinirole ErRopinirole Hcl | 23 | $1,342 |
| Primidone | 44 | $1,285 |
| Rivastigmine | 13 | $1,245 |
| Entacapone | 17 | $1,085 |
| Carbamazepine ErCarbamazepine | 14 | $1,080 |
| Pregabalin | 16 | $935 |
| Ropinirole Hcl | 47 | $880 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $474 | $90,85921 claims |
| AbbVieNamzaric | $267 | $9,98618 claims |
| Amneal Pharmaceuticals LLCRytary | $260 | $7,68515 claims |
| Upsher-smith Laboratories LLCTopiramate | $150 | $25027 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 131 neurology providers in Kansas.
Other neurology in Manhattan
- Fatma RadhiManhattan$3K
- Ivan OsorioKansas City$101.7M
- Jeffrey KaplanLenexa$1.9M
- Rajesh PahwaKansas City$889K
- Sheetal MalikTopeka$137K
- Richard DubinskyKansas City$122K
- Barbara Jean OttleyHays$116K
- Jeffrey BurnsKansas City$115K
- Douglas DavisSalina$100K
- Amanda ThuringerKansas City$87K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.